{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:40:36Z","timestamp":1781264436142,"version":"3.54.1"},"reference-count":117,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Virol."],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.2217\/fvl.10.89","type":"journal-article","created":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T06:34:21Z","timestamp":1299566061000},"page":"157-177","source":"Crossref","is-referenced-by-count":42,"title":["Atazanavir\/Ritonavir-Based Combination Antiretroviral Therapy for Treatment of HIV-1 Infection in Adults"],"prefix":"10.1080","volume":"6","author":[{"given":"Chad J","family":"Achenbach","sequence":"first","affiliation":[{"name":"Feinberg School of Medicine & Center for Global Health, Northwestern University, Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M","family":"Darin","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine & Center for Global Health, Northwestern University, Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Murphy","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine & Center for Global Health, Northwestern University, Chicago, USA"},{"name":"Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Pierre et Marie Curie, Paris, France"},{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2011,3,7]]},"reference":[{"key":"e_1_3_2_2_1_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_3_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13802-0"},{"key":"e_1_3_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1004"},{"key":"e_1_3_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2093-2099.2000"},{"key":"e_1_3_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203290-00006"},{"key":"e_1_3_2_2_6_1","unstructured":"Agarwala S GraselaD ChildM GeraldesM GeigerM O\u2018MaraE: Characterization of the steady-state pharmacokinetic (PK) profile of atazanavir (ATV) beyond the 24-hour dosing interval. Presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris France 8\u201311 July 2003."},{"key":"e_1_3_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.6.1431"},{"key":"e_1_3_2_2_8_1","unstructured":"O\u2018mara E MummaneniV RandallD et al.: BMS-232632: a summary of multiple dose pharmacokinetic food effect and drug interaction studies in healthy subjects. Presented at: 7th Conference on Retroviruses and Opportunistic Infections. CA USA 30 Jan\u20132 Feb 2000."},{"key":"e_1_3_2_2_9_1","unstructured":"Randall D AgarwalaS MummanemiV: Multiple-dose pharmacokinetics of atazanavir in healthy subjects: a summary of food effect and drug interaction studies. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA USA 27\u201330 September 2002."},{"key":"e_1_3_2_2_10_1","unstructured":"Giguere P BurryJ BeiqueL et al.: The effect of food on the pharmacokinetics of atazanavir\/ritonavir 300\/100 mg daily in HIV-infected patients. Presented at: 11th Workshop on Clinical Pharmacology of HIV Therapy. Sorrento Italy 7\u20139 April 2010."},{"key":"e_1_3_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00797-09"},{"key":"e_1_3_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00774-06"},{"key":"e_1_3_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328317a702"},{"key":"e_1_3_2_2_14_1","unstructured":"Letendre S FitzSimonsC EllisR et al.; Correlates of CSF viral loads in 1221 volunteers of the charter cohort. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. CA USA 16\u201319 February 2010."},{"key":"e_1_3_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2007.31"},{"key":"e_1_3_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181af83d6"},{"key":"e_1_3_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp317"},{"key":"e_1_3_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.028258"},{"key":"e_1_3_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp102"},{"key":"e_1_3_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00098-06"},{"key":"e_1_3_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181897bff"},{"key":"e_1_3_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1399"},{"key":"e_1_3_2_2_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0022"},{"issue":"5","key":"e_1_3_2_2_24_1","first-page":"635","article-title":"Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity.","volume":"39","author":"Lucia MB","year":"2005","unstructured":"Lucia MB , GolottaC, RutellaS, RastrelliE, SavarinoA, CaudaR: Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity.J. Acquir. Immune Defic. Syndr.39(5) , 635\u2013637 (2005).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"e_1_3_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1550-8579(07)80025-8"},{"key":"e_1_3_2_2_26_1","unstructured":"Umeh O CurrierJ ParkJG et al.; the A5223 Study Group: Sex differences in lopinavir\/ritonavir soft gel capsule pharmacokinetics among HIV-infected females and males. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. CA USA USA 25\u201328 February 2007."},{"key":"e_1_3_2_2_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296763"},{"key":"e_1_3_2_2_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn204"},{"key":"e_1_3_2_2_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000202653.49020.dd"},{"key":"e_1_3_2_2_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016209789973628"},{"key":"e_1_3_2_2_31_1","unstructured":"Mirochnick M StekA CapparelliE et al.; P1026s Protocol Team: Atazanavir pharmacokinetics with and without tenofovir during pregnancy. Presented at: T-140. 16th Conference on Retroviruses and Opportunistic Infections. Montreal Canada 8\u201311 February 2009."},{"key":"e_1_3_2_2_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32825a69d1"},{"key":"e_1_3_2_2_33_1","unstructured":"Ripamonti D CattaneoD D\u2018avolioA et al.: Steady state pharmacokinetics of ritonavir-boosted atazanavir in 31 pregnant women before and after delivery. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. CA USA 16\u201319 February 2010."},{"key":"e_1_3_2_2_34_1","unstructured":"Spencer L NeelyM MordwinkinN et al.: Intensive PK of zidovudine (AZT) lamivudine (3TC) and atazanavir (ATV) and HIV-1 viral load in breast milk and plasma in HIV+ women receiving HAART therapy.Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal Canada 8\u201311 February 2009."},{"key":"e_1_3_2_2_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318186edd0"},{"key":"e_1_3_2_2_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443150-00002"},{"key":"e_1_3_2_2_37_1","unstructured":"Eley T VandeloiseE ChildM et al.; the Atazanavir 182 Pregnancy Study Group: Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300 mg once daily \/ ritonavir 100 mg once daily + ZDV\/3TC during the third trimester in HIV+ women. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal Canada 8\u201311 February 2009."},{"key":"e_1_3_2_2_38_1","unstructured":"Kaul S BassiK DamleB et al.: Pharmacokinetic evaluation of the combination of atazanavir enteric coated didanosine and tenofovir disoproxil fumarate for a once daily antiretroviral regimen. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL USA 13\u201317 September 2003."},{"key":"e_1_3_2_2_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn383"},{"key":"e_1_3_2_2_40_1","doi-asserted-by":"publisher","DOI":"10.1086\/512086"},{"key":"e_1_3_2_2_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-008-8025-z"},{"key":"e_1_3_2_2_42_1","unstructured":"Hermida D onate JM Quereda C Moreno A et al.: Efficacy and safety of atazanavir in HIV-infected patients with liver cirrhosis. Presented at: 4th IAS Conference on HIV Pathogenesis Treatment and Prevention. Sydney Australia 22\u201325 July 2007."},{"key":"e_1_3_2_2_43_1","unstructured":"Agarwala S EleyT ChildM et al.: Pharmacokinetics of atazanavir in severely renally impaired subjects including those on hemodialysis. Presented at: 8th International Workshop on Clinical Pharmacology of HIV Therapy. Abstract no. 2. Budapest Hungary 16\u201318 April 2007."},{"key":"e_1_3_2_2_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2091-2096.2004"},{"key":"e_1_3_2_2_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0344-y"},{"key":"e_1_3_2_2_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp408"},{"key":"e_1_3_2_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61081-8"},{"key":"e_1_3_2_2_48_1","unstructured":"Agarwala S EleyT VillegasC et al.: Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec Canada 28\u201330 April 2005."},{"key":"e_1_3_2_2_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00761-07"},{"key":"e_1_3_2_2_50_1","unstructured":"Vincent I BarrailA PikettyC et al.: Pharmacokinetic parameters of tenofovir when combined with atazanavir\/ritonavir in hiv-infected patients with multiple treatment failures: A substudy of puzzle 2-ANRS 107 trial. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec Canada 28\u201330 April 2005."},{"key":"e_1_3_2_2_51_1","unstructured":"Agarwala S PerssonA EleyT et al.: Effect of famotidine 20- and 40-mg dosing regimens on the bioavilability of atazanavir with ritonavir in combination with tenofovir in healthy subjects. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. CA USA 25\u201328 February 2007."},{"key":"e_1_3_2_2_52_1","unstructured":"Wang X ChungE MahnkeL et al.: Effects of famotidine on the pharmacokinetics of atazanavir when given with ritonavir with or without tenofovir in HIV-infected subjects. Presented at: 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam The Netherlands 15\u201317 April 2009."},{"key":"e_1_3_2_2_53_1","unstructured":"Agarwala S GrayK WangY GraselaD: Pharmacokinetic effect of omeprazole on atazanavir coadminstered with ritonavir in healthy subjects. Presented at: 12th Conference on Retroviruses and Opportunistic Infections. MA USA 22\u201325 February 2005."},{"key":"e_1_3_2_2_54_1","doi-asserted-by":"crossref","unstructured":"Luber A BrowerR PeloquinC FrankI: Steady state pharmacokinetics (PK) of once daily fosamprenavir\/ritonavir (FPV\/R) and atazanavir\/ritonavir (ATV\/R) alone and in combination with 20 mg once daily of omeprazole (OMP) in healthy volunteers. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon Portugal 20\u201322 April 2006.","DOI":"10.1111\/j.1468-1293.2007.00496.x"},{"key":"e_1_3_2_2_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010367651"},{"key":"e_1_3_2_2_56_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.1.3.403"},{"key":"e_1_3_2_2_57_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250903321514"},{"key":"e_1_3_2_2_58_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.17.1732.52347"},{"key":"e_1_3_2_2_59_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969080-00009"},{"key":"e_1_3_2_2_60_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D394"},{"key":"e_1_3_2_2_61_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2004.40.11.872579"},{"key":"e_1_3_2_2_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200312050-00007"},{"key":"e_1_3_2_2_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200406010-00005"},{"key":"e_1_3_2_2_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31815ace6a"},{"key":"e_1_3_2_2_65_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct0906-367"},{"key":"e_1_3_2_2_66_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2007.0013"},{"key":"e_1_3_2_2_67_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct0904-213"},{"key":"e_1_3_2_2_68_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct0903-152"},{"key":"e_1_3_2_2_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000216371.76689.63"},{"key":"e_1_3_2_2_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp146"},{"key":"e_1_3_2_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61081-8"},{"key":"e_1_3_2_2_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181c990bf"},{"key":"e_1_3_2_2_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-5-5"},{"key":"e_1_3_2_2_74_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1102-69"},{"key":"e_1_3_2_2_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833bee1b"},{"key":"e_1_3_2_2_76_1","unstructured":"Daar E TierneyC FischlM et al.; ACTG A5202 Study Team: ACTG 5202: final results of ABC\/3TC or TDF\/FTC with either EFV or ATV\/R in treatment-naive HIV-infected patients. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. CA USA 16\u201319 February 2010."},{"key":"e_1_3_2_2_77_1","unstructured":"Cohen C ShamblawD RuaneP ElionR et al.: Single-tablet fixed-dose regimen of elvitegravir\/emtricitabine\/tenofovir disoproxil fumarate\/GS-9350 achieves a high rate of virologic suppression and GS-9350 is an effective booster. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. CA USA 16\u201319 February 2010."},{"key":"e_1_3_2_2_78_1","unstructured":"Cooper D : Safety and efficacy of three different combinaton antiretroviral regimens as initial therapy for HIV infection: week 48 data from a randomized open-label study (#LBPEB09). Presented at: 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Cape Town South Africa 19\u201322 July 2009."},{"key":"e_1_3_2_2_79_1","unstructured":"Soriano V K\u00f6ppeS MigroneH LutzT OpravilM et al.: Prospective randomized comparison of nevirapine and atazanavir\/ritonavir both combined with tenofovir DF\/emtricitabine in treatment-naive HIV-1 infected patients: ARTEN study week 48 results (#lbpeb07). Presented at: 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Cape Town South Africa 19\u201322 July 2009."},{"key":"e_1_3_2_2_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350601100213"},{"key":"e_1_3_2_2_81_1","doi-asserted-by":"publisher","DOI":"10.1086\/597119"},{"key":"e_1_3_2_2_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31802e2940"},{"key":"e_1_3_2_2_83_1","unstructured":"Deluca A BraccialeL DoinoM FabbianiM et al.: Safety and efficacy of treatment simplification to atazanavir\/ritonavir plus lamivudine in patients on two NRTIS plus atazanavir\/ritonavir with optimal virologic control: 24 weeks results from a pilot study (atazanavir and lamivudine simplification study ATLAS) (#THLBB207). Presented at: XVIII International AIDS Conference. Vienna Austria 18\u201323 July 2010."},{"key":"e_1_3_2_2_84_1","unstructured":"Mills A MildvanD PodzamczerD et al.: Safety and immunovirological activity of once daily maraviroc (MVC) in combination with ritonavir-boosted atazanavir (ATV\/R) compared with emtricitabine 200mg\/tenofovir 300mg QD (TDF\/FTC) + ATV\/R in treatment-na\u00efve patients infected with CCR5-tropic HIV-1 (study a4001078): a week 24 planned interim analysis (#THLBB203). Presented at: XVIII International AIDS Conference. Vienna Austria 18\u201323 July 2010."},{"key":"e_1_3_2_2_85_1","unstructured":"Kozal M LupoS DejesusE MolinaJ et al.: The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300mg bid plus raltegravir (RAL) 400mg BID (ATV+RAL) in treatment-na\u00efve HIV-infected subjects (#THLBB204). Presented at: XVIII International AIDS Conference. Vienna Austria 18\u201323 July 2010."},{"key":"e_1_3_2_2_86_1","doi-asserted-by":"publisher","DOI":"10.1086\/386291"},{"key":"e_1_3_2_2_87_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3816-3824.2005"},{"key":"e_1_3_2_2_88_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X65439"},{"key":"e_1_3_2_2_89_1","doi-asserted-by":"publisher","DOI":"10.1086\/466531"},{"key":"e_1_3_2_2_90_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.005447"},{"key":"e_1_3_2_2_91_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1004-269"},{"key":"e_1_3_2_2_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-008-8010-6"},{"key":"e_1_3_2_2_93_1","doi-asserted-by":"publisher","DOI":"10.1086\/381444"},{"key":"e_1_3_2_2_94_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283177f38"},{"key":"e_1_3_2_2_95_1","unstructured":"Guillemi S HarrisM KantersS et al.: Can total bilirubin levels be used to predict high atazanavir trough concentration among HIV+ adults receiving ritonavir-boosted atazanavir? (#THPE0159). Presented at: XVIII International AIDS Conference. Vienna Austria 18\u201323 July 2010."},{"key":"e_1_3_2_2_96_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0276"},{"key":"e_1_3_2_2_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280c56ae1"},{"key":"e_1_3_2_2_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32813aee35"},{"key":"e_1_3_2_2_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f17503"},{"key":"e_1_3_2_2_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000247571.88256.90"},{"key":"e_1_3_2_2_101_1","doi-asserted-by":"publisher","DOI":"10.1089\/08892220050075264"},{"key":"e_1_3_2_2_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283352ed5"},{"key":"e_1_3_2_2_103_1","doi-asserted-by":"publisher","DOI":"10.1086\/517497"},{"key":"e_1_3_2_2_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31819a226f"},{"key":"e_1_3_2_2_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm413"},{"key":"e_1_3_2_2_106_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832ba904"},{"key":"e_1_3_2_2_107_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2009.0039"},{"key":"e_1_3_2_2_108_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181a5701c"},{"key":"e_1_3_2_2_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00690.x"},{"key":"e_1_3_2_2_110_1","unstructured":"Aberg J OvertonT GuptaS FalconR RyanR De La Rosa G: METABOLIK (Metabolic Evaluation in Treatment Naives Assessing the Impact of Two Boosted Protease Inhibitors on Lipids and Other Markers): comparison of the metabolic effects of darunavir\/ritonavir versus atazanavir\/ritonavir over 12 weeks (#WEPE0111) Presented at: XVIII International AIDS Conference. Vienna Austria 18\u201323 July 2010."},{"key":"e_1_3_2_2_111_1","doi-asserted-by":"publisher","DOI":"10.1086\/597776"},{"key":"e_1_3_2_2_112_1","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e3181641b26"},{"key":"e_1_3_2_2_113_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000244200.11006.55"},{"key":"e_1_3_2_2_114_1","first-page":"4","article-title":"Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.","volume":"3","author":"La Porte CJ","year":"2006","unstructured":"La Porte CJ , BackDJ, BlaschkeT et al.: Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.Rev. Antivir. Ther.3 , 4\u201314 (2006).","journal-title":"Rev. Antivir. Ther."},{"key":"e_1_3_2_3_2_1","unstructured":"UNAIDS report on the global AIDS epidemic www.unaids.org\/globalreport\/default.htm"},{"key":"e_1_3_2_3_3_1","unstructured":"Prescribing information for Reyataz http:\/\/packageinserts.bms.com\/pi\/pi_reyataz.pdf"},{"key":"e_1_3_2_3_4_1","unstructured":"University of Liverpool: HIV drug interaction www.hiv-druginteractions.org"}],"container-title":["Future Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fvl.10.89","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:58:04Z","timestamp":1715993884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fvl.10.89"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.2217\/fvl.10.89"],"URL":"https:\/\/doi.org\/10.2217\/fvl.10.89","relation":{},"ISSN":["1746-0794","1746-0808"],"issn-type":[{"value":"1746-0794","type":"print"},{"value":"1746-0808","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}